UNSPSC 51111771: Vinleucinol

This classification denotes a vinca alkaloid compound with the molecular formula C51H69N5O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MUJ5BW9BWR, chemically known as vincaleukoblastine, o(sup 4)-deacetyl-3-de(methoxycarbonyl)-3-(((1-(ethoxycarbonyl)-2-methylbutyl)amino)carbonyl)-, (3(1s,2s))- but generally known as vinleucinol, which bears US NIH Compound Identifier 72163. European Medicines Agency schedules Vinleucinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00067MIG.

UNSPSC 51111771 Vinleucinol is a Commodity code that does not reflect the actual work state and local governments are buying under this classification. The recent opportunities posted against this code involve procurement of naloxone, medical and first aid supplies, pharmaceuticals, and OTC products—none of which are vinleucinol-specific. The mismatch between code name and solicited scope suggests either a taxonomy misalignment in the state and local procurement system or that this code captures a narrow pharmaceutical input with minimal direct government purchasing activity.

The issuing bodies include a county health department (Seminole County, Florida), a state health and human services commission (Texas HHS), a city fire department (Tampa), and a multistate cooperative purchasing alliance (MMCAP, Minnesota). Geographic activity centers on Florida, Texas, and the MMCAP footprint spanning Minnesota and Oregon, with little evidence of activity in other states. Representative recent opportunities include Seminole County's IFB for naloxone and drug deactivation systems (1,900 units of naloxone and 800 systems annually, posted June 30, 2026, response due July 26, 2023); the City of Tampa's IFB for medical and first aid supplies to the Tampa Fire Department Rescue Division (169 line items, estimated contract value $700,000, posted March 25, 2026, due March 13, 2026, sheltered for certified Small Local Business Enterprises with a 5 percent bid discount); Minnesota MMCAP's RFP for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers (proposals due March 26, 2026, contract effective July 1, 2026); and the Texas HHS Commission's RFI on Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions (posted April 3, 2026). Activity under this code is sparse and geographically fragmented, with no clear repeat buyer or procurement pattern that would signal sustained demand.